AAAAAA

   
Results: 1-11 |
Results: 11

Authors: GACHON F CHARRIER S KWIATKOWSKI F BESSE G CURE H CHASSAGNE J FERRIERE JP PENAULTLLORCA F DAUPLAT J CHOLLET P
Citation: F. Gachon et al., EXPRESSION OF CYTOSOLIC THYMIDINE KINASE IN THE PROLIFERATIVE BREAST-CARCINOMA AFTER PRIMARY CHEMOTHERAPY - THERAPEUTIC INDICATION, European journal of cancer, 34, 1998, pp. 469-469

Authors: CURE H VANPRAAGH I CHARRIER S KWIATKOWSKI F FERRIERE JP CHOLLET P
Citation: H. Cure et al., PHASE-I OF DOXORUBICIN AND IFOSFAMIDE ASSOCIATION FOR FIRST LINE ADVANCED BREAST-CANCER (ABC), Annals of oncology, 9, 1998, pp. 115-115

Authors: FERRIERE JP ASSIER I CURE H CHARRIER S KWIATKOWSKI F ACHARD JL DAUPLAT J CHOLLET P
Citation: Jp. Ferriere et al., PRIMARY CHEMOTHERAPY IN BREAST-CANCER - CORRELATION BETWEEN TUMOR RESPONSE AND PATIENT OUTCOME, American journal of clinical oncology, 21(2), 1998, pp. 117-120

Authors: CHARRIER S CHASSAGNE J CURE H BAY JO COMMUNAL Y PORTEFAIX G FERRIERE JP BETAIL G PLAGNE R CHOLLET P
Citation: S. Charrier et al., MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS AFTER INDUCTION CHEMOTHERAPY RUBICIN-VINORELBINE-CYCLOPHOSPHAMIDE-FLUOROURACIL) AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN BREAST-CANCER, Bone marrow transplantation, 22(9), 1998, pp. 845-851

Authors: CHARRIER S FERRIERE JP KWIATKOWSKI F CURE H VANPRAAGH I FEILLEL V ASSIER I BAY JO DAUPLAT J CHOLLET P
Citation: S. Charrier et al., OPTIMAL DURATION OF NEOADJUVANT CHEMOTHERAPY - 3 OR 4 VERSUS 6 CYCLESIN 3 SCHEMES FOR OPERABLE BREAST-CANCER, European journal of cancer, 33, 1997, pp. 360-360

Authors: CHOLLET P CHARRIER S BRAIN E CURE H VANPRAAGH I FEILLEL V DELATOUR M DAUPLAT J MISSET JL FERRIERE JP
Citation: P. Chollet et al., CLINICAL AND PATHOLOGICAL RESPONSE TO PRIMARY CHEMOTHERAPY IN OPERABLE BREAST-CANCER, European journal of cancer, 33(6), 1997, pp. 862-866

Authors: FERRIERE JP CHARRIER S CURE H KWIATKOWSKI F COURTADON M BELEMBAOGO E DELATOUR M ACHARD JL DAUPLAT J CHOLLET P
Citation: Jp. Ferriere et al., ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN-CONTAINING REGIMEN FOR 326 STAGE-II BREAST CANCERS - 15-YEAR RESULTS, American journal of clinical oncology, 20(3), 1997, pp. 219-225

Authors: CURE H CHARRIER S FERRIERE JP VANPRAAGH I ASSIER I FEILLEL V DELATOUR M BAY JO ACHARD JL DAUPLAT J CHOLLET P
Citation: H. Cure et al., RESULTS OF 3 NEOADJUVANT CHEMOTHERAPY REG IMEN FOR OPERABLE BREAST-CANCER, Bulletin du cancer, 84(1), 1997, pp. 31-34

Authors: VANPRAGGH I FERRIERE JP CURE H FEILLEL V LEBOUEDEC G DELATOUR M ROLHION C CHARRIER S ASSIER I MISSET JL DAUPLAT J CHOLLET P
Citation: I. Vanpraggh et al., COMPARISON OF 3 NEOADJUVANT CHEMOTHERAPY REGIMENS FOR OPERABLE BREAST-CANCER, European journal of cancer, 31A, 1995, pp. 53-53

Authors: FLEURY J TORTOCHAUX J LEGROS M CURE H KWIATKOWSKI F FERRIERE JP TRAVADE P DIONET C GAILLARD G CHASSAGNE J BIGNON YJ VANPRAAGH I BELEMBAOGO E CHOLLET P PLAGNE R
Citation: J. Fleury et al., PRONOSTIC VALUE OF BETA-2-MICROGLOBULIN I N YOUNG-ADULTS WITH HODGKINS-DISEASE, Bulletin du cancer, 81(7), 1994, pp. 625-631

Authors: ATTIASOBOL J FERRIERE JP CURE H KWIATKOWSKI F ACHARD JL VERRELLE P FEILLEL V DELATOUR M LAFAYE C DELOCHE C DAUPLAT J DOLY A ROZAN R CHOLLET P
Citation: J. Attiasobol et al., TREATMENT RESULTS, SURVIVAL AND PROGNOSTIC FACTORS IN 109 INFLAMMATORY BREAST CANCERS - UNIVARIATE AND MULTIVARIATE-ANALYSIS, European journal of cancer, 29A(8), 1993, pp. 1081-1088
Risultati: 1-11 |